We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
Testosterone for Women
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA · Last reviewed May 10, 2026
Women produce testosterone in the ovaries and adrenal glands throughout life, and testosterone declines steadily from the late 20s onward — falling further at menopause. The Global Consensus Position Statement on testosterone therapy for women (2019) endorses testosterone as an evidence-based treatment for hypoactive sexual desire disorder in postmenopausal women. It is widely prescribed off-label in the United States because no female-specific testosterone product is FDA-approved.
Reproductive-age women produce 0.1–0.4 mg/day of testosterone — about 10× less than men but pharmacologically meaningful. Levels decline with age and drop further with surgical menopause or chemotherapy. Total testosterone levels in women span roughly 15–70 ng/dL; free testosterone is the more clinically relevant measure.
Total and free testosterone are checked alongside SHBG (sex hormone-binding globulin), which heavily influences free testosterone. Many standard reference ranges in U.S. labs were derived from male populations and are unhelpful for female interpretation; an experienced clinician interprets values in context.
Libido improvement is typically the first noticeable change, often within 4–8 weeks. Energy and mental clarity follow over the first 3 months. Muscle and strength changes require resistance training and become apparent over months. Testosterone will not solve all causes of low libido — relational, sleep, and mood factors matter — but it addresses the hormonal contribution.
Current evidence does not show an increased breast cancer risk with physiologic-dose testosterone in women, and some data suggest a neutral or favorable effect on breast tissue. Long-term randomized data are limited; risk-benefit is individualized.
At physiologic doses with appropriate monitoring, yes. Side effects are dose-related and reversible.
Yes. The Global Consensus 2019 endorses testosterone for postmenopausal hypoactive sexual desire disorder.
Most commonly as a compounded cream applied daily.
Libido improvement is often noticeable in 4–8 weeks; full effect by 3–6 months.
At properly dosed female regimens, no. Voice and clitoral changes occur only at supraphysiologic doses.
Yes — combined regimens are common and often more effective than either alone for libido and energy.
Total and free testosterone, SHBG, and (sometimes) lipids and liver function during titration.
No female-specific product is FDA-approved in the U.S. Compounded preparations and off-label use of male products are how it is currently prescribed.
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
Currently onboarding clinicians in all 50 states.
Estradiol is the primary estrogen prescribed for menopause symptoms. Kindr’s board-certifi…
Progesterone →Progesterone is essential for most women on HRT. Board-certified doctors prescribe bioiden…
Best HRT for Menopause →What is the best HRT for menopause? It depends on your symptoms, history, and preference. …
HRT and Hair Loss →Menopause hair loss is hormonal. HRT, testosterone, and prescription hair treatments can h…
Information on this page is for educational purposes only. Prescription medications require clinical evaluation and provider approval. Individual results vary. Not an emergency service.